Pharmafile Logo

Wilmington Healthcare appoints new Account Director

September 26, 2017 | Wilmington 

Healthcare intelligence provider Wilmington Healthcare, which incorporates Binley’s, NHiS, Wellards and HSJ, has strengthened its salesforce with the appointment of Gareth Thurston as Account Director.

In his new post, Gareth will be overseeing a number of key accounts across the Wilmington Healthcare portfolio and ensuring that the relevant specialist teams meet their objectives.

Gareth who has worked in sales and marketing roles in the healthcare industry for nearly 30 years, joins Wilmington Healthcare from Cello Health Consulting Ltd, where he was a consultant.

Prior to that, Gareth spent nearly 10 years at Novartis Pharmaceuticals UK Limited, where he held a number of different roles, including Marketing Manager and Franchise Lead for the company’s transplantation portfolio. His final post at the company was Brand Lead, Ophthalmology.   Before joining Novartis, Gareth held senior sales and product manager positions at Gilead Sciences Ltd in their anti-infective franchise.

Gareth Thomas, Managing Director of Wilmington Healthcare, said: “Having worked in sales and marketing roles in the healthcare industry for nearly 30 years, Gareth Thurston brings a wealth of experience to his new job.

“He will play an important role in supporting our clients to achieve greater success, whilst helping our business to continue to go from strength to strength. We are very pleased to welcome him to our team.” 

- PMLiVE
Gareth Thurston

This content was provided by Wilmington Healthcare

Company Details

 Latest Content from  Wilmington Healthcare 

Wilmington Healthcare appoints new director to lead cloud-based healthcare customer intelligence tool

Paul Rowe to lead intelligence tool that allows Industry to gain the complete picture of their changing NHS customer base and employ precision planning to access target customers and markets.

LOOKING AHEAD: UNDERSTANDING THE NHS CUSTOMER’S PRIORITIES FOR 2022/23

The recently published operational planning guidance describes what the NHS needs to achieve this year. Wilmington Healthcare’s Oli Hudson explores some of its critical themes and what they mean for...

NAVIGATING 2022: THE FIVE CRITICAL SHIFTS PHARMA NEEDS TO EMBRACE

With a stormy outlook predicted for health and care, Wilmington Healthcare’s Oli Hudson looks at the five critical shifts that pharma should focus on as it navigates its way through...

CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE

As well as creating new structures, the reforms underway within the NHS will see a considerable movement of people and power across the new Integrated Care Systems. Wilmington Healthcare’s Victoria...

We must be candid about our use of healthcare data if we want to win back public trust

As the government announces a delay to a new GP data sharing initiative amid privacy concerns, Gareth Thomas, Managing Director of Wilmington Healthcare, explains why industry must move fast to...

Wilmington Healthcare appoints new Solutions Director

Kirsty Fryer has been promoted to the role of Solutions Director for Wilmington Healthcare

Understanding the role of provider collaboratives

Oli Hudson, Content Director at Wilmington Healthcare, takes a look at the new groups of providers that are expected to play a pivotal role in integrating care.

How does the government plan to reshape the NHS?

Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care

Integrated NHS finances: what do they mean for High Cost Drugs?

Oli Hudson and Steve How, of Wilmington Healthcare, explore NHS England’s new system-level funding and its impact on prescribing for High Cost Drugs

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas